Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: Corcept Therapeutics Incorporated, a pharmaceutical company, is engaged in the discovery, development, and commercialization of drugs for the treatment of metabolic, psychiatric, and oncologic disorders in the United States. The company focuses on disorders that are associated with a steroid hormone called cortisol. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing?s syndrome, who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing mifepristone, an active ingredient in Korlym, which is in Phase III study for treatment of the psychotic features of psychotic depression; and in Phase I study for the treatment of triple-negative breast cancer. In addition, it discovers and develops three series of novel selective GR-II antagonists. The company has research and development agreements with Argenta D
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||72.68%||Sales Growth - Q/Q||12.07%||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-46.21%||ROE||-210.77%||ROI|
|Current Ratio||2.85||Quick Ratio||2.76||Long Term Debt/Equity||0.77||Debt Ratio||1.47|
|Gross Margin||96.87%||Operating Margin||-58.27%||Net Profit Margin||-69.1%||Dividend Payout Ratio|
|Cash From Financing Activities||15.52 M||Cash From Investing Activities||-30 K||Cash From Operating Activities||-1.78 M||Gross Profit||9.8 M|
|Net Profit||-4.83 M||Operating Profit||-4.03 M||Total Assets||48.22 M||Total Current Assets||44.19 M|
|Total Current Liabilities||15.53 M||Total Debt||32.78 M||Total Liabilities||37.65 M||Total Revenue||10.1 M|
|High 52 week||17.19||Low 52 week||9.78||Last close||14.36||Last change||2.21%|
|RSI||43.75||Average true range||0.45||Beta||0.99||Volume||325.31 K|
|Simple moving average 20 days||1.81%||Simple moving average 50 days||7.91%||Simple moving average 200 days||18.95%|
|Performance Week||2.21%||Performance Month||8.05%||Performance Quart||34.58%||Performance Half||21.9%|
|Performance Year||17.32%||Performance Year-to-date||7.49%||Volatility daily||1.61%||Volatility weekly||3.6%|
|Volatility monthly||7.37%||Volatility yearly||25.52%||Relative Volume||267.92%||Average Volume||720.16 K|
|New High||New Low|
2020-06-03 11:30:03 | Has Corcept Therapeutics CORT Outpaced Other Medical Stocks This Year?
2020-06-03 11:30:03 | Why Is Corcept CORT Up 8.2% Since Last Earnings Report?
2020-05-18 06:23:06 | Should You Worry About Corcept Therapeutics Incorporated's NASDAQ:CORT CEO Pay?
2020-05-13 13:16:24 | 6 Stocks John Hussman Continues to Buy
2020-05-12 07:45:00 | Should You Climb on Board the Corcept Therapeutics Train?
2020-05-10 22:46:10 | Were Hedge Funds Right About Corcept Therapeutics Incorporated CORT?
2020-05-06 18:27:00 | Corcept Therapeutics Shows Rising Price Performance With Jump To 85 RS Rating
2020-05-05 20:26:46 | Edited Transcript of CORT earnings conference call or presentation 4-May-20 9:00pm GMT
2020-05-05 14:50:06 | Corcept CORT Q1 Earnings Top Estimates, Revenues Rise Y/Y
2020-05-05 08:31:12 | New Strong Buy Stocks for May 5th
2020-05-05 01:02:01 | Corcept Therapeutics Incorporated CORT Q1 2020 Earnings Call Transcript
2020-05-04 19:05:11 | Corcept Therapeutics CORT Tops Q1 Earnings and Revenue Estimates
2020-04-27 12:00:04 | Are You Looking for a Top Momentum Pick? Why Corcept Therapeutics CORT is a Great Choice
2020-04-22 06:43:58 | Should You Be Adding Corcept Therapeutics NASDAQ:CORT To Your Watchlist Today?
2020-04-13 08:31:12 | Corcept Therapeutics' Shares March Higher, Can It Continue?
2020-04-02 09:51:01 | Why You Shouldn't Bet Against Corcept Therapeutics CORT Stock
2020-04-01 08:30:10 | CORCEPT THERAPEUTICS PUBLISHES ABSTRACT IN THE JOURNAL OF THE ENDOCRINE SOCIETY
2020-03-26 12:06:34 | Update: Corcept Therapeutics NASDAQ:CORT Stock Gained 88% In The Last Five Years
2020-03-21 11:30:03 | Corcept CORT Down 24.9% Since Last Earnings Report: Can It Rebound?
2020-03-12 08:30:10 | Corcept Therapeutics Appoints Gregg Alton to Board of Directors
2020-03-03 09:00:28 | These 3 Biotech Stocks Are Outperforming Their Peers — Here's Why
2020-02-21 14:25:07 | Corcept CORT Q4 Earnings In-Line with Estimates, Up Y/Y
2020-02-20 18:15:11 | Corcept Therapeutics CORT Meets Q4 Earnings Estimates
2020-02-19 12:10:05 | Why Corcept CORT Could Beat Earnings Estimates Again
2020-02-18 11:04:04 | What's in Store for Corcept CORT This Earnings Season?
2020-02-17 12:30:05 | Corcept Therapeutics CORT to Report Q4 Results: What Awaits?
2020-01-30 06:45:53 | How Corcept Therapeutics Incorporated NASDAQ:CORT Can Impact Your Portfolio Volatility
2020-01-09 08:40:01 | Tyme Initiates Dosing in Pivotal Pancreatic Cancer Study
2020-01-08 10:18:03 | Tyme Out-Licenses Cancer Candidate to Eagle Pharma, Stock Up
2020-01-07 10:21:03 | Soleno SLNO Ends Enrollment in Prader-Willi Syndrome Study
2020-01-07 09:51:02 | Intrexon's Blood Cancer Drug Gets Orphan Drug Status From FDA
2020-01-07 09:17:02 | Catalyst Gives Preliminary Firdapse Estimates & Other Updates
2020-01-07 07:54:12 | New Strong Buy Stocks for January 7th
2019-12-31 07:49:35 | Read This Before Selling Corcept Therapeutics Incorporated NASDAQ:CORT Shares
2019-12-10 10:46:43 | Hedge Funds Are Buying Corcept Therapeutics Incorporated CORT
2019-12-07 11:31:04 | Why Is Corcept CORT Down 8.9% Since Last Earnings Report?
2019-11-19 08:51:01 | Can The Uptrend Continue for Corcept Therapeutics?
2019-11-14 08:52:01 | Options Traders Expect Huge Moves in Corcept CORT Stock
2019-11-08 18:08:00 | Edited Transcript of CORT earnings conference call or presentation 7-Nov-19 10:00pm GMT
2019-11-08 10:31:03 | Corcept CORT Earnings Beat in Q3, Korlym Boosts Sales